Subcutaneous beloranib: Completed Phase IIb enrollment

Zafgen completed enrollment of 152 Type II diabetics with severe obesity in the double-blind, placebo-controlled, Australian Phase IIb ZAF-203 trial evaluating 1.2 and 1.8 mg subcutaneous beloranib tw...